Jefferies Financial Group Reaffirms Hold Rating for Chimerix (NASDAQ:CMRX)

Chimerix (NASDAQ:CMRX)‘s stock had its “hold” rating reissued by Jefferies Financial Group in a research report issued to clients and investors on Wednesday,Benzinga reports. They presently have a $8.50 price objective on the biopharmaceutical company’s stock, down from their prior price objective of $10.00. Jefferies Financial Group’s target price would indicate a potential upside of 0.83% from the company’s current price.

Other equities analysts have also issued reports about the stock. Wedbush restated a “neutral” rating and set a $8.55 price target (up from $7.00) on shares of Chimerix in a research report on Wednesday. HC Wainwright restated a “neutral” rating and set a $8.55 target price (down from $11.00) on shares of Chimerix in a report on Wednesday.

Chimerix Stock Performance

Shares of CMRX stock opened at $8.43 on Wednesday. Chimerix has a fifty-two week low of $0.75 and a fifty-two week high of $8.47. The stock’s fifty day moving average is $4.14 and its two-hundred day moving average is $2.21. The firm has a market capitalization of $758.16 million, a P/E ratio of -8.97 and a beta of 0.32.

Insider Activity

In other news, CEO Michael T. Andriole sold 7,370 shares of the business’s stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $4.52, for a total value of $33,312.40. Following the sale, the chief executive officer now directly owns 609,603 shares of the company’s stock, valued at approximately $2,755,405.56. The trade was a 1.19 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last 90 days, insiders have sold 20,760 shares of company stock valued at $91,175. 13.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the company. Bender Robert & Associates purchased a new position in Chimerix during the 4th quarter valued at about $37,000. Susquehanna Fundamental Investments LLC acquired a new stake in shares of Chimerix during the fourth quarter worth about $59,000. Jane Street Group LLC purchased a new position in shares of Chimerix in the fourth quarter valued at approximately $62,000. Diadema Partners LP acquired a new position in shares of Chimerix in the fourth quarter valued at approximately $101,000. Finally, Squarepoint Ops LLC purchased a new stake in Chimerix during the 4th quarter worth approximately $130,000. 45.42% of the stock is currently owned by hedge funds and other institutional investors.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.